Suzhou Ribo Life Science (HKG:6938) said the European Medicines Agency has approved a Phase 2b clinical trial of its core product, vortosiran, for stroke prevention in patients with atrial fibrillation, according to a Tuesday Hong Kong bourse filing.
The approval allows the company to begin the global multi-regional ORBIT-XI-AF study, advancing vortosiran into the next stage of clinical development.
The Kiyo Bank (TYO:8370) said that its board agreed to establish a wholly owned investment advisory services subsidiary in August, broadening its financial services beyond traditional banking, according to a Tuesday filing on the Tokyo Stock Exchange.The Tokyo-listed bank said that the new company, The Kiyo Mirai Investment Co., will provide investment advisory services and will be established with capital of 100 million yen.The operations of the new unit are subject to regulatory conditions, and the company expects the establishment of the unit to have a limited impact on its results for the fiscal year ending March 31, 2027.
Yandal Resources (ASX:YRL) said a diamond drill hole completed below the Flushing Meadows deposit within the Ironstone Well-Barwidgee gold project in Western Australia provided evidence of primary fresh rock mineralization continuity at the deposit, according to a Tuesday Australian bourse filing.The company said the program highlighted the presence of multiple parallel mineralized structures within the hanging wall, above and east of the current mineral resource.It hit an intercept of 4.8 meters at 2.3 grams per tonne grade of gold from 175.2 meters.Four initial follow-up reverse circulation drill holes were completed adjacent to the diamond drill hole to assess mineralization continuity of the recently identified parallel hanging-wall mineralization into fresh rock, the company said.Yandal Resources' shares fell 6% in recent trading on Tuesday.
ESR REIT (SGX:J91U) distribution per unit or DPU was up 2.4% during the first half of the year to SG$0.1151 from SG$0.11239 a year earlier, according to a Tuesday filing with the Singapore Exchange.Amount available for distribution rose 3.2% to SG$93 million from SG$90.1 million.Net property income fell 2.2% to SG$162.7 million compared with SG$166.3 million in the year-ago period.Gross revenue edged down 0.3% year over year to SG$222.3 million from SG$222.9 million.